Arch Therapeutics, Inc. (ARTH) EPS Estimated At $-0.01

December 24, 2017 - By Nellie Frank

 Arch Therapeutics, Inc. (ARTH) EPS Estimated At $ 0.01

Analysts expect Arch Therapeutics, Inc. (OTCMKTS:ARTH) to report $-0.01 EPS on December, 25.After having $-0.01 EPS previously, Arch Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 12.59% or $0.068 during the last trading session, reaching $0.472. About 605,726 shares traded or 36.92% up from the average. Arch Therapeutics, Inc. (OTCMKTS:ARTH) has 0.00% since December 24, 2016 and is . It has underperformed by 16.70% the S&P500.

Arch Therapeutics, Inc. operates as a life science medical device company. The company has market cap of $72.66 million. The firm develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. It currently has negative earnings. The Company’s primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures.

More notable recent Arch Therapeutics, Inc. (OTCMKTS:ARTH) news were published by: Globenewswire.com which released: “Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and …” on September 20, 2017, also Seekingalpha.com with their article: “Arch Therapeutics Seals The Deal On Strong Trial Data For Its AC5 Hemostatic …” published on August 16, 2016, Globenewswire.com published: “Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman …” on September 06, 2017. More interesting news about Arch Therapeutics, Inc. (OTCMKTS:ARTH) were released by: Seekingalpha.com and their article: “Tiny Arch Therapeutics Just Doubled: Time To Dump?” published on April 11, 2016 as well as Seekingalpha.com‘s news article titled: “Can Arch Therapeutics Stop The Bleeding… In Patients, That Is” with publication date: June 27, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.